Treatment for liver inflammation depends on the cause. Fatty liver–related inflammation may improve with gradual weight loss, physical activity, and treating metabolic risks; some adults with noncirrhotic NASH and moderate-to-advanced fibrosis may be eligible for resmetirom. Viral hepatitis, alcohol-related disease, autoimmune disease, bile duct problems, and drug-induced injury need cause-specific medical care 1 2.
Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →What does an inflamed liver mean?
Liver inflammation means liver cells are irritated or injured. It may show up as high liver enzymes on blood work, symptoms like fatigue or nausea, imaging changes, or biopsy findings, but it does not tell you the cause by itself 6.
Liver inflammation vs fatty liver vs hepatitis vs fibrosis
Fatty liver means excess fat has built up in the liver. Hepatitis means liver inflammation, which may come from viruses, alcohol, fat buildup, immune disease, medications, supplements, or toxins. Fibrosis means scarring after repeated injury; cirrhosis is advanced scarring that changes liver structure and function 3.
Metabolic dysfunction-associated steatotic liver disease, or MASLD, is the newer term for what many people know as nonalcoholic fatty liver disease, or NAFLD. Metabolic dysfunction-associated steatohepatitis, or MASH, is the newer term for NASH: fatty liver with inflammation and liver-cell injury that can lead to fibrosis 1 7.
Why the cause matters more than the symptom
The same abnormal liver enzyme result can have very different next steps. A person with viral hepatitis may need antiviral evaluation, while a person with medication-related injury may need a careful drug review, and a person with MASLD may need a plan for weight, insulin resistance, and cardiovascular risk 1 3.
What are the first signs of an inflamed liver?
Early liver inflammation often has no clear symptoms. Many people first learn something is wrong after routine blood tests show elevated ALT, AST, alkaline phosphatase, bilirubin, or other liver-related markers 6.
Common symptoms
- Fatigue or feeling run down
- Nausea or poor appetite
- Right upper belly discomfort
- Bloating or feeling full sooner than usual
- Itching, if bile flow is involved
Warning symptoms
Why many people have no symptoms
The liver has a large reserve. Mild or moderate inflammation can be present before daily function changes. That is why follow-up testing matters when liver enzymes are abnormal, even if you feel well 6.
What causes liver inflammation?
Liver inflammation can come from metabolic, infectious, alcohol-related, medication-related, immune, bile duct, genetic, heart-related, or cancer-related causes. The right treatment depends on matching the cause to the plan 3.
- MASLD or NAFLD: excess liver fat linked with metabolic risk, including insulin resistance, obesity, type 2 diabetes, high blood pressure, and abnormal cholesterol 1.
- MASH or NASH: fatty liver with inflammation and liver-cell injury, which can progress to fibrosis, cirrhosis, liver failure, or liver cancer in some people 2 3.
- Alcohol-related liver disease: liver injury from alcohol exposure; severity can range from fatty liver to alcoholic hepatitis, fibrosis, or cirrhosis 3.
- Viral hepatitis: hepatitis A, B, C, D, or E can inflame the liver and may need testing, vaccination counseling, monitoring, or antiviral care depending on the virus.
- Medication, supplement, and toxin-related injury: drug-induced liver injury, or DILI, is assessed with exposure history, serial labs, and clinician review; suspected cases should not be managed alone 6.
- Autoimmune, bile duct, genetic, heart-related, and cancer-related causes: autoimmune hepatitis, primary biliary cholangitis, bile duct obstruction, hemochromatosis, Wilson disease, congestive hepatopathy, and liver tumors need targeted evaluation 3.
How do doctors find the cause of liver inflammation?
Doctors look for a pattern. Within the first evaluation, they usually combine history, blood tests, medication and supplement review, and sometimes imaging to decide whether the pattern looks metabolic, viral, immune, bile duct, alcohol-related, or drug-related 6.
History
A clinician may ask about alcohol use, acetaminophen use, prescriptions, over-the-counter medicines, supplements, recent travel, viral exposure, sexual or blood exposure risks, weight change, diabetes, cholesterol, family history, pregnancy, and symptoms like itching or jaundice 6.
Blood tests
Common labs include ALT, AST, alkaline phosphatase, bilirubin, albumin, INR, platelet count, blood count, viral hepatitis tests, autoimmune markers, iron studies, and metabolic labs. The pattern matters: for example, a bile duct pattern may look different from a liver-cell injury pattern 6.
Imaging and fibrosis tools
Ultrasound, elastography, CT, or MRI may be used when appropriate. Noninvasive fibrosis scores and elastography can help estimate scarring risk, while biopsy may be discussed when diagnosis or fibrosis stage remains unclear 7.
What is the best treatment for liver inflammation?
There is no single best remedy for every inflamed liver. The best treatment is the one that addresses the cause while also lowering the chance of fibrosis, cirrhosis, and other complications 1 3.
| Likely cause or situation | What usually helps | What to watch |
|---|---|---|
| MASLD / NAFLD or MASH / NASH | Gradual weight loss when appropriate, physical activity, nutrition changes, and care for diabetes, insulin resistance, blood pressure, and cholesterol 1. | Rapid weight loss and malnutrition can worsen liver disease 1. |
| Noncirrhotic NASH with moderate-to-advanced fibrosis | Specialist evaluation; resmetirom may be considered with diet and exercise for eligible adults 2. | Resmetirom approval used a surrogate endpoint, and postapproval study follow-up is required 2. |
| Alcohol-related inflammation | Stopping alcohol with medical support; supervised withdrawal care may be needed for some people 13. | Sudden alcohol withdrawal can be dangerous for people with dependence 13. |
| Viral hepatitis | Testing and antiviral or specialist care depending on the virus. | Some viral hepatitis can become chronic and needs follow-up. |
| Drug-induced liver injury | Medication, supplement, and toxin review with a clinician; monitoring labs over time 6. | Do not stop essential prescribed medicines or restart suspected products without guidance. |
| Autoimmune or bile duct disease | Specialist diagnosis and prescription treatment based on the exact disease. | Untreated bile duct blockage or autoimmune hepatitis can become serious. |
Fatty liver or MASH/NASH
For MASLD and MASH, NIDDK states that weight loss can reduce liver fat, and greater weight loss may reduce liver inflammation and fibrosis. Physical activity can help even without weight loss 1. If you are working on weight, our guides to insulin resistance, protein for weight loss, and weight-loss plateaus may help you prepare for a clinician visit.
Alcohol-related inflammation
If alcohol is contributing, stopping alcohol is central, but some people need medical support to do this safely. People with heavy daily alcohol use should not assume they can stop suddenly without risk, because withdrawal can be serious 13.
Viral hepatitis, DILI, autoimmune disease, and bile duct disease
These causes need diagnosis-specific care. Drug-induced liver injury assessment relies on a careful exposure history, serial liver blood tests, and expert review; the goal is to identify the likely cause without interrupting needed treatment unsafely 6.
3-min quiz
Thinking about weight care as part of metabolic health?
If your clinician has linked fatty liver risk with weight or insulin resistance, Chia may be able to help with weight care—not liver disease treatment. Eligible adults can be reviewed for compounded semaglutide injection or compounded tirzepatide tablets or injections. A licensed US provider must review your health history, and a prescription is never guaranteed. Compounded drugs are not FDA-approved.
Can an inflamed liver go back to normal?
Sometimes, yes. Early fatty liver inflammation may improve when the cause is addressed, but the outlook changes if significant fibrosis or cirrhosis has developed 1 3.
Fibrosis stage is one of the most important pieces of the picture. Early scarring may improve in some settings when the injury stops, while cirrhosis is advanced scarring that needs ongoing specialist care and monitoring for complications 3.
Follow-up may include repeat liver enzymes, bilirubin, platelet count, fibrosis scores, ultrasound, elastography, or other tests. Improvement is tracked over time rather than by symptoms alone 6.
What should you eat or avoid when your liver is inflamed?
For fatty liver–related inflammation, food changes work best when they create gradual, sustainable weight loss and improve metabolic risk. Rapid weight loss and malnutrition can make liver disease worse, so the goal is steady change, not crash dieting 1.
Foods and habits that often help
- Fiber-rich foods such as vegetables, beans, lentils, fruit, and whole grains.
- Lean protein spread through the day, which can help with fullness and muscle support during weight loss.
- Unsaturated fats from foods like olive oil, nuts, seeds, and fish when they fit your plan.
- Portion awareness, especially for calorie-dense foods.
- Regular physical activity, which NIDDK notes is beneficial for NAFLD even without weight loss 1.
What to limit
- Alcohol, especially if liver enzymes are high or alcohol-related disease is possible.
- Sugary drinks, including soda, sweet tea, energy drinks, and many juices.
- Large amounts of refined carbs, such as sweets, white bread, and many snack foods.
- Highly processed foods that make calorie control harder.
- Unreviewed supplements or herbal products, because some can damage the liver 1.
What about milk thistle or silymarin?
Silymarin, a compound from milk thistle, has been studied in randomized NASH trials, but it is not a proven stand-alone treatment for liver inflammation. One randomized trial studied silymarin for nonalcoholic steatohepatitis, while broader reviews note that herbal liver products still need better trials and clearer dosing standards 8 9.
What medicines are used for fatty liver inflammation or NASH?
Medicine choices depend on the diagnosis and fibrosis stage. Resmetirom is the main FDA-approved medicine specifically for certain adults with noncirrhotic NASH and moderate-to-advanced fibrosis, while other drugs remain investigational or are used for related metabolic conditions 2.
Resmetirom
Resmetirom, brand name Rezdiffra, is a thyroid hormone receptor-beta partial activator approved for adults with noncirrhotic NASH with moderate-to-advanced fibrosis, used with diet and exercise. In the FDA-cited 54-month randomized trial, safety and efficacy were evaluated at month 12 using biopsy-based surrogate endpoints for inflammation and scarring 2 4.
Accelerated approval means the FDA accepted a surrogate endpoint reasonably likely to predict clinical benefit, while requiring postapproval study follow-up to verify and describe the benefit. Side effects, drug interactions, gallbladder-related risks, pregnancy considerations, and whether a person truly has the indicated stage of disease should be reviewed by the prescribing clinician 2.
Investigational medicines
Efruxifermin, an FGF21 analog, has shown safety and efficacy signals in phase 2b randomized trials for NASH/MASH, including HARMONY results reported at 24 and 96 weeks, but it remains investigational rather than routine approved treatment 10 11. Cotadutide, a GLP-1/glucagon receptor dual agonist, has been studied in people with overweight or obesity and type 2 diabetes, but it is not a general liver-inflammation treatment 12.
GLP-1 and GIP/GLP-1 medicines
Semaglutide, known by brand names including Ozempic and Wegovy, is a GLP-1 receptor agonist; tirzepatide, known by brand names including Mounjaro and Zepbound, is a dual GIP/GLP-1 receptor agonist. These medicines are used for weight or diabetes indications depending on the product, and weight loss can be part of MASLD care, but they should not be framed as direct treatment for liver inflammation or NASH unless a clinician is using evidence for that exact purpose 1.
Side effects can include nausea, vomiting, diarrhea, constipation, reflux, dehydration risk, gallbladder problems, and rare pancreatitis concerns. People with certain endocrine cancer histories, pregnancy, severe gastrointestinal disease, or complex liver disease need individualized review before weight-loss medication is considered 14 15.
| Option | Evidence status | Important limit |
|---|---|---|
| Gradual weight loss and physical activity | Official guidance supports this for NAFLD/MASLD; 3% to 5% weight loss may reduce liver fat, and 7% to 10% may be needed to reduce inflammation and fibrosis 1. | Must be gradual; rapid weight loss and malnutrition can worsen liver disease. |
| Resmetirom / Rezdiffra | FDA-approved for adults with noncirrhotic NASH with moderate-to-advanced fibrosis, with diet and exercise 2. | Not for every inflamed liver; approval used surrogate endpoints and requires follow-up study. |
| Efruxifermin | Phase 2b randomized trial data show signals in NASH/MASH 10 11. | Investigational, not routine approved care. |
| Cotadutide | Studied in people with overweight or obesity and type 2 diabetes 12. | Not a standard liver-inflammation treatment. |
| Silymarin / milk thistle | Studied in randomized NASH research 8. | Not proven as a stand-alone treatment; supplements can harm the liver. |
Where Chia may fit if liver inflammation is linked with weight and metabolic health
Chia does not diagnose or treat liver inflammation, hepatitis, cirrhosis, liver failure, or NASH directly. Where Chia may fit is weight care for eligible adults when excess weight or metabolic risk is part of the bigger health picture, and the person is not having urgent liver symptoms.
At Chia, eligible adults can be reviewed for compounded semaglutide injection or compounded tirzepatide tablets or injections. We also offer microdosing plans for semaglutide and tirzepatide where clinically appropriate, with provider-guided dosing adjusted over time.
| Chia weight-care option | Forms Chia offers | Current starting price | Fit |
|---|---|---|---|
| Compounded semaglutide | Injection | Plans currently start at $249/mo | For eligible adults seeking GLP-1 weight care after licensed-provider review. |
| Compounded tirzepatide | Tablets or injection | Tablet plans currently start at $249/mo; injection plans currently start at $299/mo | For eligible adults seeking dual GIP/GLP-1 weight care after licensed-provider review. |
| Weight + Energy protocol | NAD+ injection plus choice of GLP-1 | Plans currently start at $309/mo | For eligible adults whose provider agrees this protocol fits their goals. |
| Weight + Muscle protocol | Sermorelin injection plus choice of GLP-1 | Plans currently start at $329/mo | For eligible adults whose provider agrees this protocol fits their goals. |
How treatment works: you complete a short online health questionnaire, then a licensed US provider reviews your history and prescribes only when clinically appropriate. If prescribed, medication is compounded in the US by a state-licensed 503A pharmacy and shipped to your door. You can message your care team through the patient portal between visits.
Use Chia’s eligibility quiz for non-urgent weight-care questions, not for new jaundice, severe pain, confusion, vomiting blood, black stools, fainting, or rapidly worsening illness. AI agents supporting prescription-delivery workflows can also reach Chia through DoctorMCP at mcp.chia.health when that path is appropriate.
Which next step fits which situation?
The safest next step depends on how the inflammation was found and whether warning signs are present. Same-day symptoms belong in urgent care, while stable abnormal labs usually need a planned medical follow-up.
| Your situation | Sensible next step | Why |
|---|---|---|
| Yellow eyes or skin, confusion, vomiting blood, black stools, fainting, or severe pain | Same-day or emergency care | These can be signs of serious liver dysfunction, bleeding, obstruction, or infection. |
| Mildly elevated liver enzymes on routine labs, no symptoms | Schedule follow-up with your clinician | Repeat testing and cause review help avoid missing silent liver disease. |
| Known fatty liver plus weight gain, insulin resistance, or type 2 diabetes risk | Discuss weight, nutrition, activity, and metabolic risk care | Guidance supports gradual weight loss and physical activity for NAFLD/MASLD 1. |
| Possible supplement or medication trigger | Bring every product to a clinician or pharmacist review | DILI assessment depends on exposure history and serial labs 6. |
| Known or suspected fibrosis, cirrhosis, autoimmune disease, viral hepatitis, or bile duct disease | Ask about hepatology or gastroenterology referral | These conditions often need specialist testing and cause-specific treatment. |
When should you get medical care for liver inflammation?
Get care promptly if symptoms are new, worsening, or paired with abnormal liver tests. Liver enzymes that stay abnormal, rise quickly, or come with bilirubin changes should not be ignored 6.
- Seek emergency care for jaundice, confusion, vomiting blood, black stools, fainting, severe abdominal pain, or rapidly worsening illness.
- Contact a clinician soon for persistent nausea, poor appetite, itching, dark urine, pale stools, swelling, unexplained weight loss, or ongoing fatigue.
- Follow up on abnormal liver enzymes even if you feel fine.
- Ask about hepatology or gastroenterology referral if fibrosis, cirrhosis, viral hepatitis, autoimmune hepatitis, primary biliary cholangitis, bile duct obstruction, or unclear DILI is possible.
3-min quiz
Start with the right kind of care
If you have urgent liver symptoms, seek in-person or emergency care. If your goal is non-urgent weight care and a clinician has connected your metabolic health with weight, you can start Chia’s online review. A prescription requires medical evaluation and is not guaranteed; compounded medications are dispensed through state-licensed 503A pharmacies and are not FDA-approved.
The fastest safe path is to find the cause. Some causes need urgent care, antivirals, stopping alcohol with support, medication review, or specialist treatment. For fatty liver–related inflammation, gradual weight loss and physical activity may help, but crash dieting can make liver disease worse.
Sometimes mild inflammation improves when a short-term trigger passes, but you should not assume it will. Ongoing inflammation can lead to scarring. Follow-up testing helps show whether the liver is improving or whether more evaluation is needed.
It depends on the cause and severity. Medication-related injury, alcohol-related inflammation, viral hepatitis, and fatty liver disease can have very different timelines. Your clinician may track liver enzymes, bilirubin, platelets, imaging, or fibrosis markers over weeks to months.
No. Fatty liver means excess fat is present in the liver. MASH or NASH means fatty liver plus inflammation and liver-cell injury. That distinction matters because MASH or NASH can increase the risk of fibrosis and later complications.
No. Silymarin has been studied in NASH research, but it is not a proven stand-alone treatment for liver inflammation. Supplements can also harm the liver or interact with medicines, so review them with a clinician before using them.
GLP-1 medicines are used for weight or diabetes indications depending on the product, and weight loss can be part of fatty liver care. They should not be viewed as direct treatment for liver inflammation or NASH unless your clinician is using evidence for your exact situation. Compounded GLP-1 medications are not FDA-approved and do not have FDA-evaluated outcomes data.
It is usually wise to avoid alcohol until you have medical guidance. For fatty liver risk, limiting sugary drinks, excess refined carbs, and highly processed foods can help. Avoid unreviewed herbs or supplements, because some can injure the liver.
It can be dangerous when it comes with jaundice, confusion, vomiting blood, black stools, fainting, severe abdominal pain, swelling, fever with severe illness, or rapidly worsening weakness. It is also more concerning when fibrosis, cirrhosis, viral hepatitis, autoimmune disease, bile duct obstruction, or drug-induced liver injury is possible.
References
- 1.National Institute of Diabetes and Digestive and Kidney Diseases. Treatment for NAFLD & NASH. NIDDK. 2024.
- 2.U.S. Food and Drug Administration. FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. FDA News Release. 2024.
- 3.Zhang CY, Yuan WG, He P, Lei JH, Wang CX. Current investigations for liver fibrosis treatment. Frontiers in Pharmacology. 2023.
- 4.Harrison SA, Bedossa P, Guy CD, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. The New England Journal of Medicine. 2024.
- 5.Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019.
- 6.Senior JR, et al. Liver Safety Assessment: Required Data Elements and Best Practices for Data Collection and Standardization in Clinical Trials. Drug Safety. 2014.
- 7.Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L. NASH: regulatory considerations for clinical drug development. Hepatology. 2022.
- 8.Wah Kheong C, Nik Mustapha NR, Mahadeva S. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology. 2017.
- 9.Asgharpour A, et al. Evidence-based herbal treatments in liver diseases. World Journal of Gastroenterology. 2024.
- 10.Harrison SA, Frias JP, Neff G, et al. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. The Lancet Gastroenterology & Hepatology. 2023.
- 11.Noureddin M, Frias JP, Neff GW, et al. Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet. 2025.
- 12.Parker VER, Robertson D, Erazo-Tapia E, et al. Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes. Nature Metabolism. 2023.
- 13.American Society of Addiction Medicine. The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management. Journal of Addiction Medicine. 2020.
- 14.Novo Nordisk. Wegovy (semaglutide) injection prescribing information. 2024.
- 15.Eli Lilly and Company. Zepbound (tirzepatide) injection prescribing information. 2024.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
